Main info

Identifier:

HOVON 41 AL Amyloidosis

Sponsor:

HOVON

Included patients:

70

Active sites:

13

(of 13)

Title:

Autologous Stem Cell Transplantation for Patients with AL Amyloidosis: A Prospective Phase II Study.

Timeline

Flow

Details

Phase:

Prospective Phase II study

Monitoring Type:

Objectives:

Eligibility

Inclusion Criteria:

• Age under 66 years
• MGUS, multiple myeloma stage I
• Histologically documented systemic AL amyloidosis (see appendix C)
• Untreated or previously treated with maximal 3 courses of melphalan and prednisone
• The patient must give informed consent according to the rules of the hospital.

Exclusion Criteria:

• Prior malignancies diagnosed less than 5 years ago, except non-melanoma skin tumours or stage 0 (in situ) cervical carcinoma. Note: Prior malignancies diagnosed and treated longer than 5 years ago, and in which case it is likely that the patient is cured, are no exclusion criteria.
• Patients with familial variants of systemic amyloidosis.
• Severe pulmonary, neurologic, psychiatric, cardiac, liver or metabolic disease not related to AL amyloidosis.

Participating Sites

= Active hospitals

= Inactive hospitals